Daré Bioscience, Inc.
DARE$20M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO21 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
DARE News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
DARE-BV1clindamycin phosphate vaginal gel, 2%
Bacterial Vaginosis
Tamoxifen
Vulvar Atrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DARE-BV1clindamycin phosphate vaginal gel, 2% | Phase 3 | Bacterial Vaginosis | - | - |
Tamoxifen | Phase 2 | Vulvar Atrophy | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply